178 related articles for article (PubMed ID: 36915128)
1. Immunological and tumor-intrinsic mechanisms mediate the synergistic growth suppression of experimental glioblastoma by radiotherapy and MET inhibition.
Silginer M; Papa E; Szabó E; Vasella F; Pruschy M; Stroh C; Roth P; Weiss T; Weller M
Acta Neuropathol Commun; 2023 Mar; 11(1):41. PubMed ID: 36915128
[TBL] [Abstract][Full Text] [Related]
2. Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models.
Mangani D; Weller M; Seyed Sadr E; Willscher E; Seystahl K; Reifenberger G; Tabatabai G; Binder H; Schneider H
Neuro Oncol; 2016 Dec; 18(12):1610-1621. PubMed ID: 27286797
[TBL] [Abstract][Full Text] [Related]
3. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
[TBL] [Abstract][Full Text] [Related]
4. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
[TBL] [Abstract][Full Text] [Related]
5. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
[TBL] [Abstract][Full Text] [Related]
6. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
7. Biological Role and Therapeutic Targeting of TGF-β
Seystahl K; Papachristodoulou A; Burghardt I; Schneider H; Hasenbach K; Janicot M; Roth P; Weller M
Mol Cancer Ther; 2017 Jun; 16(6):1177-1186. PubMed ID: 28377490
[TBL] [Abstract][Full Text] [Related]
8. Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.
Garnett J; Chumbalkar V; Vaillant B; Gururaj AE; Hill KS; Latha K; Yao J; Priebe W; Colman H; Elferink LA; Bogler O
Neoplasia; 2013 Jan; 15(1):73-84. PubMed ID: 23359207
[TBL] [Abstract][Full Text] [Related]
9. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
Goodwin CR; Lal B; Zhou X; Ho S; Xia S; Taeger A; Murray J; Laterra J
Cancer Res; 2010 Apr; 70(7):2932-41. PubMed ID: 20233866
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models.
Quijano-Rubio C; Silginer M; Weller M
J Neurooncol; 2022 Nov; 160(2):299-310. PubMed ID: 36355258
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Tran TT; Uhl M; Ma JY; Janssen L; Sriram V; Aulwurm S; Kerr I; Lam A; Webb HK; Kapoun AM; Kizer DE; McEnroe G; Hart B; Axon J; Murphy A; Chakravarty S; Dugar S; Protter AA; Higgins LS; Wick W; Weller M; Wong DH
Neuro Oncol; 2007 Jul; 9(3):259-70. PubMed ID: 17522330
[TBL] [Abstract][Full Text] [Related]
12. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J
J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431
[TBL] [Abstract][Full Text] [Related]
13. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas.
Papachristodoulou A; Silginer M; Weller M; Schneider H; Hasenbach K; Janicot M; Roth P
Clin Cancer Res; 2019 Dec; 25(23):7189-7201. PubMed ID: 31530630
[TBL] [Abstract][Full Text] [Related]
16. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation.
Lal B; Xia S; Abounader R; Laterra J
Clin Cancer Res; 2005 Jun; 11(12):4479-86. PubMed ID: 15958633
[TBL] [Abstract][Full Text] [Related]
17. Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo.
Uchinokura S; Miyata S; Fukushima T; Itoh H; Nakano S; Wakisaka S; Kataoka H
Int J Cancer; 2006 Feb; 118(3):583-92. PubMed ID: 16106403
[TBL] [Abstract][Full Text] [Related]
18. Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
Gramatzki D; Herrmann C; Happold C; Becker KA; Gulbins E; Weller M; Tabatabai G
PLoS One; 2013; 8(5):e63527. PubMed ID: 23667632
[TBL] [Abstract][Full Text] [Related]
19. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.
Hu B; Guo P; Bar-Joseph I; Imanishi Y; Jarzynka MJ; Bogler O; Mikkelsen T; Hirose T; Nishikawa R; Cheng SY
Oncogene; 2007 Aug; 26(38):5577-86. PubMed ID: 17369861
[TBL] [Abstract][Full Text] [Related]
20. P2X7 receptor as predictor gene for glioma radiosensitivity and median survival.
Gehring MP; Kipper F; Nicoletti NF; Sperotto ND; Zanin R; Tamajusuku AS; Flores DG; Meurer L; Roesler R; Filho AB; Lenz G; Campos MM; Morrone FB
Int J Biochem Cell Biol; 2015 Nov; 68():92-100. PubMed ID: 26358881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
